AB680 + zimberelimab + nab-paclitaxel + gemcitabine

**AB680 + zimberelimab + nab-paclitaxel + gemcitabine** is an investigational four-drug combination therapy designed for the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC)[5][1]. The regimen consists of: - **AB680 (quemliclustat):** A potent, selective, reversible small-molecule competitive inhibitor of CD73, which targets the extracellular adenosine pathway to alleviate adenosine-mediated immunosuppression within the tumor microenvironment[3][5]. - **zimberelimab (GLS-010):** A fully human monoclonal antibody targeting programmed cell death protein 1 (PD-1), aiming to restore anti-tumor T cell activity through immune checkpoint blockade[4][5]. - **nab-paclitaxel (Abraxane):** A nanoparticle albumin-bound formulation of paclitaxel, a microtubule inhibitor used as cytotoxic chemotherapy for pancreatic cancer[5][1]. - **gemcitabine:** A nucleoside analog that inhibits DNA synthesis, serving as standard-of-care chemotherapy for pancreatic cancer[5][1]. This regimen is being studied in clinical trials for its potential to improve outcomes in patients with treatment-naïve metastatic pancreatic cancer by synergistically combining immune modulation (CD73 inhibition and PD-1 blockade) with cytotoxic chemotherapy[5][3][1].

Brand names

Abraxane (nab-paclitaxel)

Other names

AB680-based regimenAB-680-based regimenAB 680-based regimenAB680 combination therapyAB-680 combination therapyAB 680 combination therapy